Monovalent Anti-properdin antibodies and antibody fragments
Patent Information
- Application Number
- JP2024095141
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-01-30
- Filing Date
- 2024-06-12
- Publication Date
- 2024-11-14
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Uncontrolled activation or underregulation of the alternative complement pathway leads to systemic inflammation and tissue damage, with existing therapies failing to effectively modulate properdin activity, a key regulator of this pathway.
Development of monovalent antibodies and antibody fragments that selectively bind to properdin, inhibiting its activity and preventing the formation of membrane attack complexes, thereby regulating the alternative complement pathway.
These antibodies effectively reduce immune complex aggregation and membrane attack complex formation, providing therapeutic benefits for diseases mediated by alternative complement pathway dysregulation.
Smart Images

Figure 00000044_0000 
Figure 00000044_0001 
Figure 00000045_0000
Abstract
Description
[Background technology]
[0001] The complement system plays a central role in the clearance of immune complexes and immune responses against infectious agents, foreign antigens, virus-infected cells and tumor cells. Complement activation occurs mainly through three pathways: the classical pathway, the lectin pathway and the alternative pathway. Uncontrolled activation or poor regulation of the alternative pathway can lead to systemic inflammation, cellular injury and tissue damage. The alternative pathway has been implicated in the pathogenesis of a growing number of diverse diseases. Properdin positively regulates the activation of the alternative pathway by binding to and stabilizing the C3 and C5 convertase complexes (C3bBb and C3bnBb). Inhibition or modulation of properdin activity is an important therapeutic strategy to alleviate symptoms and slow disease progression associated with dysregulation of the alternative pathway. This demand for effective modulation of properdin activity remains unmet. Summary of the Invention [Means for solving the problem]
[0002] Described herein are isolated monovalent antibodies and their antibody fragments that specifically or substantially specifically bind to properdin and selectively block the activation of the alternative complement pathway.By inhibiting the functional activity of properdin, the monovalent antibodies described herein inhibit the formation of membrane attack complex induced by the alternative complement pathway.In addition, the selective binding of single properdin molecules to monovalent antibodies can reduce undesirable immune complexes caused by aggregation.Therefore, selective targeting of single properdin monomers or multimers may increase clinical benefits for patients with diseases mediated by complement alternative pathway dysregulation.
[0003] In one embodiment, the disclosure relates to an isolated monovalent antibody or antibody fragment thereof that binds to human properdin. In certain embodiments, the antibody or fragment is a camelid antibody. In certain embodiments, the antibody or fragment is a single domain antibody. In certain embodiments, the antibody or fragment binds to TSR0 and / or TSR1 of human properdin. In certain embodiments, the antibody or fragment binds to an epitope of the amino acid sequence LCQPCRSPRWSLWSTWAPCSVTCSEGSQLRYRRCVGWNGQ (SEQ ID NO: 8). In certain embodiments, the antibody or fragment binds to mouse properdin with an affinity of less than 50 nM. In certain embodiments, the antibody or fragment comprises at least one or all of the three CDRs selected from a) CDR-H1 comprising the amino acid sequence GRIFEVNMMA (SEQ ID NO: 9); b) CDR-H2 comprising the amino acid sequence RVGTTX1YADSVKG (SEQ ID NO: 10), where X1 is a polar or non-polar amino acid; and c) CDR-H3 comprising the amino acid sequence LQYX2RYGGAEY (SEQ ID NO: 11), where X2 is a polar amino acid. In certain embodiments, CDR-H2 comprises the amino acid sequence RVGTTVYADSVKG (SEQ ID NO: 12). In certain embodiments, CDR-H3 comprises the amino acid sequence LQYDRYGGAEY (SEQ ID NO: 13). In certain embodiments, CDR-H2 comprises the amino acid sequence RVGTTTYADSVKG (SEQ ID NO: 15). In certain embodiments, CDR-H3 has the amino acid sequence LQYSRYGGAEY (SEQ ID NO: 14). In certain embodiments, CDR-H3 has the amino acid sequence LQYDRYGGAEY (SEQ ID NO: 13). In certain embodiments, CDR-H3 has the amino acid sequence LQYDRYGGAEY (SEQ ID NO: 13). In certain embodiments, CDR-H3 has the amino acid sequence LQYSRYGGAEY (SEQ ID NO: 14). In certain embodiments, the antibody or fragment comprises three CDRs: a) CDR-H1 having the amino acid sequence GRISSIIHMA (SEQ ID NO: 16), b) CDR-H2 having the amino acid sequence RVGTTVYADSVKG (SEQ ID NO: 12), c) CDR-H3 having the amino acid sequence LQYEKHGGADY (SEQ ID NO: 17).In certain embodiments, the antibody comprises six CDRs: a) CDR-H1 having the amino acid sequence GYIFTNYPIH (SEQ ID NO: 18); b) CDR-H2 having the amino acid sequence FIDPGGGYDEPDERFRD (SEQ ID NO: 19); c) CDR-H3 having the amino acid sequence RGGGYYLDY (SEQ ID NO: 20); d) CDR-L1 having the amino acid sequence RASQDISFFLN (SEQ ID NO: 21); e) CDR-L2 having the amino acid sequence YTSRYHS (SEQ ID NO: 22); and f) CDR-L3 having the amino acid sequence QHGNTLPWT (SEQ ID NO: 23). In certain embodiments, the antibody comprises six CDRs: a) CDR-H1 having the amino acid sequence GFSLTTYGVH (SEQ ID NO: 24); b) CDR-H2 having the amino acid sequence VIWSGGDTDYNASFIS (SEQ ID NO: 25); c) CDR-H3 having the amino acid sequence NKDYYTNYDFTMDY (SEQ ID NO: 26); d) CDR-L1 having the amino acid sequence KSSQSVLYSSNQKNFLA (SEQ ID NO: 27); e) CDR-L2 having the amino acid sequence WASTRES (SEQ ID NO: 28); and f) CDR-L3 having the amino acid sequence HQYLSSYT (SEQ ID NO: 29). In certain embodiments, the antibody comprises six CDRs: a) CDR-H1 having the amino acid sequence GYTFIDYWIE (SEQ ID NO: 30); b) CDR-H2 having the amino acid sequence EIFPGSGTINHNEKFKD (SEQ ID NO: 31); c) CDR-H3 having the amino acid sequence EGLDY (SEQ ID NO: 32); d) CDR-L1 having the amino acid sequence SASSSVSYIY (SEQ ID NO: 33); e) CDR-L2 having the amino acid sequence DTSTLAS (SEQ ID NO: 34); and f) CDR-L3 having the amino acid sequence QQWSRNPFT (SEQ ID NO: 35).In certain embodiments, the antibody comprises six CDRs: a) CDR-H1 having the amino acid sequence GFSLTSYGVH (SEQ ID NO: 36); b) CDR-H2 having the amino acid sequence VIWSGGSTDYNAAFIS (SEQ ID NO: 37); c) CDR-H3 having the amino acid sequence NKDFYSNYDYTMDY (SEQ ID NO: 38); d) CDR-L1 having the amino acid sequence KSSQSVLYSSNQKNFLA (SEQ ID NO: 27); e) CDR-L2 having the amino acid sequence WASTRES (SEQ ID NO: 28); and f) CDR-L3 having the amino acid sequence HQYLSSYT (SEQ ID NO: 29). In certain embodiments, the antibody comprises six CDRs: a) CDR-H1 having the amino acid sequence GYTXTAYGIN (SEQ ID NO: 39), b) CDR-H2 having the amino acid sequence YIYIGNGYTDYNEKFKG (SEQ ID NO: 40), c) CDR-H3 having the amino acid sequence SGWDEDYAMDF (SEQ ID NO: 41), d) CDR-L1 having the amino acid sequence RASENIYSYLA (SEQ ID NO: 42), e) CDR-L2 having the amino acid sequence HAKTLAE (SEQ ID NO: 43), and f) CDR-L3 having the amino acid sequence QHHYGPPPT (SEQ ID NO: 44). In certain embodiments, the antibody or fragment inhibits the activity of human properdin.
[0004] In one embodiment, the present disclosure relates to the use of an isolated monovalent antibody or antibody fragment thereof that binds to human properdin in a method of treating a disease mediated by complement alternative pathway dysregulation or in the manufacture of a medicament for treating a disease mediated by complement alternative pathway dysregulation.
[0005] In one embodiment, the present disclosure relates to a method of treating a disease mediated by alternative pathway dysregulation, comprising administering an effective amount of an isolated monovalent antibody or antibody fragment thereof to a patient in need thereof, wherein the antibody or antibody fragment binds to human properdin. In certain embodiments, the disease is selected from the group consisting of autoimmune thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (Buerger's disease), asthma (e.g., severe asthma), C3 glomerulopathy (C3G), Gaucher's disease, hidradenitis suppurativa, Behcet's disease, severe burns, early sepsis, dermatomyositis, pneumococcal meningitis, Alzheimer's disease, cancer metastasis, acute respiratory distress syndrome (ARDS), acute lung injury (ACI), transfusion-associated lung injury (TRALI), hemodialysis-associated thrombosis, epidermolysis bullosa acquisita (EBA), uveitis, Parkinson's disease, primary biliary atresia, antineutrophil cytoplasmic antibody (ANCA) vasculitis, retinal degeneration, widespread thrombotic microangiopathy (TMA), and / or pulmonary edema (PE). ), extensive TMA (APS), hematopoietic stem cell therapy (HSCT) TMA, age-related macular degeneration (AMD), pre-eclampsia, hemolysis, elevated liver enzymes and thrombocytopenia (HELLP) syndrome, multiple sclerosis, antiphospholipid syndrome (APS), relapsing polychondritis, ischemic disorders, stroke, graft-versus-host disease (GvHD), chronic obstructive pulmonary disease (COPD), emphysema, atherosclerosis, acute coronary syndrome, hemorrhagic shock, rheumatoid arthritis, dialysis (cardiovascular risk), cardiovascular disease, placental malaria, antiphospholipid syndrome (APS) pregnancy loss, membranoproliferative (MP) glomerulonephritis, membranous nephritis, encephalitis, encephalopathy, N-methyl-D-aspartate (NMDA) receptor antibody encephalitis, malarial hemolytic crisis, abdominal aortic aneurysm (AAA) or thoracoabdominal aortic aneurysm (TAA).
[0006] In one embodiment, the present disclosure relates to a method for inhibiting alternative pathway membrane attack complex assembly, comprising administering to a patient in need thereof an effective amount of an antibody, antibody derivative or fragment thereof. In certain embodiments, the method inhibits alternative pathway dependent hemolysis.
[0007] In some embodiments, the antibody or fragment thereof comprises the sequence:
[0008] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGSGGGGSGGGGSLEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSS (SEQ ID NO: 45) In some embodiments, the antibody or fragment thereof comprises the sequence:
[0009] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGRISSIIHMAWFRQAPGKERELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS (SEQ ID NO: 46) In some embodiments, the antibody or fragment thereof comprises the sequence:
[0010] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGDGGGGDGGGGEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSS (SEQ ID NO: 47) In some embodiments, the antibody or fragment thereof comprises the sequence:
[0011] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGEGGGGEGGGGEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSS (SEQ ID NO: 48) In some embodiments, the antibody or fragment thereof comprises the sequence:
[0012] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGRISSIIHMAWVRQAPGKQRELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS (SEQ ID NO: 49) In some embodiments, the antibody or fragment thereof comprises the sequence:
[0013] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGDGGGGDGGGGEVQLLESGGGLVQPGGSLRLSCAASGRISSIIHMAWFRQAPGKERELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS (SEQ ID NO: 50) In some embodiments, the antibody or fragment thereof comprises the sequence:
[0014] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGEGGGGEGGGGEVQLLESGGGLVQPGGSLRLSCAASGRISSIIHMAWFRQAPGKERELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS (SEQ ID NO: 51) In some embodiments, the antibody or fragment thereof comprises the sequence:
[0015] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGDGGGGDGGGGEVQLVESGGGLVQPGGSLRLSCAASGRISSIIHMAWVRQAPGKQRELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS (SEQ ID NO: 52) In some embodiments, the antibody or fragment thereof comprises the sequence:
[0016] LEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSSRKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 53) In some embodiments, the antibody or fragment thereof is LVP058 anti-properdin monovalent antibody V linked to hG1 without the C1q binding domain. HH and contains the following sequence:
[0017] LEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSSPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 54) In some embodiments, the antibody or fragment thereof is linked to anti-albumin V via a (G4S)3 linker. HH LVP058 anti-properdin monovalent antibody V linked to HH and contains the following sequence:
[0018] LEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS (SEQ ID NO: 55) definition As used herein, the term "monovalent antibody or antibody fragment thereof" refers to a V antibody or antibody fragment thereof directed against an antigen, such as a single properdin molecule. H or V HHThe term "antibody" refers to an antibody or antigen-binding fragment thereof that contains one binding domain such as a nucleotide sequence. In one embodiment, the antigen molecule bound is part of a trimer or higher multimer of properdin monomers. Antibodies, including monovalent antibodies or antibody fragments thereof, generally bind to specific antigens with high specificity.
[0019] As used herein, the term "single domain antibody" defines a molecule in which the antigen binding site is present on and formed by a single immunoglobulin domain. Generally, the antigen binding site of a single variable domain of an immunoglobulin is formed by no more than three CDRs. The single variable domain may be any combination of e.g. a light chain variable domain sequence (V L sequence) or a suitable fragment thereof, or a heavy chain variable domain sequence (V H Array or V HH sequence, etc.) or a suitable fragment thereof.
[0020] As used herein, the term "camelid antibody" refers to an antibody derived from a species of camelid, such as camel, dromedary, llama, alpaca or guanaco. Camelid antibodies differ from most other mammalian antibodies in that they lack light chains and therefore contain only heavy chains with complete and diverse antigen-binding capacity (Hamers-Casterman, C. et al., Nature, 363:446-8, 1993).
[0021] As used herein, "V HH The term "antibody" refers to a single heavy chain variable domain antibody devoid of light chains. For example, V HH The chains can be constructed according to the type found in Camelidae or cartilaginous fishes, which do not originally have light chains, or synthetic V HH and non-immunized V HHEach heavy chain includes a variable region encoded by a V exon, a D exon, and a J exon. HH is a natural V antibody, such as a camelid antibody. HH It may be an antibody or a recombinant protein comprising a heavy chain variable domain.
[0022] As used herein, the term "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that binds properdin is substantially free of contaminants such as antibodies that do not bind properdin). An "isolated" antibody is also one that has been identified and separated and / or recovered from components of its natural environment that are substances that may interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
[0023] As used herein, the term "specific binding" of an antibody or fragment thereof, polypeptide, or peptidomimetic is binding to a target molecule that is measurably different from binding to a non-target molecule. As used herein, specific binding refers to greater than 95% binding preference to a specific antigen over background ("non-specific") binding. "Substantially specific" binding refers to greater than about 80% binding preference to a specific antigen over background. Binding can be measured using a variety of methods, including, but not limited to, Western blot, immunoblot, enzyme-linked immunosorbent assay ("ELISA"), radioimmunoassay ("RIA"), immunoprecipitation, surface plasmon resonance, biolayer interferometry, chemiluminescence, fluorescence polarization, phosphorescence, immunohistochemistry, matrix-assisted laser desorption / ionization time-of-flight ("MALDI-TOF") mass spectrometry, microcytometry, microarrays, microscopy, fluorescence-activated cell sorting ("FACS"), and flow cytometry.
[0024] As used herein, the term "human properdin" refers to a soluble glycoprotein of 469 amino acids found in plasma that has seven thrombospondin type I repeats (TSR) with the N-terminal domain, TSR0, being the cleavage domain. Human properdin, a 53 kDa protein, contains a signal peptide (amino acids 1-28) and six different TSR repeats of approximately 60 amino acids each: amino acids 80-134 (TSR1), amino acids 139-191 (TSR2), amino acids 196-255 (TSR3), amino acids 260-313 (TSR4), amino acids 318-377 (TSR5), and amino acids 382-462 (TSR6). Properdin is formed by the assembly of rod-shaped monomers into oligomers, such as cyclic dimers, trimers, and tetramers. The amino acid sequence of human properdin can be found in the GenBank database under the following accession numbers: For human properdin, see, for example, GenBank Accession No. AAA36489; - See 002612, AAH15756, AAP43692, S29126 and CAA40914. Properdin is a positive regulator of the alternative complement activation cascade. Known binding ligands for properdin include C3b, C3bB and C3bBb (Blatt, A. et al., Immunol. Rev., 274:172-90, 2016).
[0025] As used herein, the term "mouse properdin" refers to a soluble glycoprotein of 457 amino acids found in plasma that has seven TSRs and is truncated at the N-terminal domain, TSR0. Mouse properdin, a 50 kDa protein, contains a signal peptide (amino acids 1-24) and six distinct TSR repeats of approximately 60 amino acids each: amino acids 73-130 (TSR1), amino acids 132-187 (TSR2), amino acids 189-251 (TSR3), amino acids 253-309 (TSR4), amino acids 311-372 (TSR5), and amino acids 374-457 (TSR6). Mouse properdin is formed by the assembly of rod-shaped monomers into oligomers, such as cyclic dimers, trimers, and tetramers. The amino acid sequence of mouse properdin can be found, for example, in the GenBank database (GenBank Accession Nos. P11680 and S05478).
[0026] As used herein, the term "TSR0 domain" refers to the cleavage domain of properdin that precedes the TSR1 domain of properdin. For example, the TSR0 domain of human properdin includes amino acids 28-76.
[0027] As used herein, the term "TSR1 domain" refers to the domain of properdin adjacent to the TSR0 domain of properdin. For example, the TSR1 domain of human properdin includes amino acids 77-134.
[0028] As used herein, the term "activity of properdin" refers to the biological activity of properdin, including but not limited to binding interactions that lead to stabilization of C3 / C5 convertase. Properdin binds most avidly to the C3b,Bb alternative pathway C3 / C5 convertase, but also binds to C3b, C3b,B, and C3b,Bb). One function is to stabilize the C3b,Bb complex, allowing for higher alternative pathway activation (Pangburn, M., Methods Enzymol., 162:639-53, 1988; Nolan, K. & Reid, K., Methods Enzymol., 223:35-46, 1993). Properdin promotes the formation of alternative pathway C3 convertase by increasing the binding of factor B to the P,C3b complex. Thus, properdin is a facilitator (positive regulator) of complement activation. Properdin has also been implicated in initiating activation of the alternative pathway by binding to target surfaces and initiating the formation of C3 / C5 convertases (Kemper C. & Hourcade, D., Mol. Immunol., 45:4048-56, 2008).
[0029] As used herein, the term "alternative pathway" refers to one of three pathways of complement activation (the others being the classical pathway and the lectin pathway). The alternative pathway is generally activated by bacteria, parasites, viruses or fungi, although IgA antibodies and some IgL chains have also been reported to activate this pathway.
[0030] As used herein, the term "alternative complement pathway dysregulation" refers to any abnormality in the ability of the alternative complement pathway to defend the host against pathogens, to clear immune complexes and damaged cells, and for immune regulation. Alternative complement pathway dysregulation can occur in both the fluid phase and on the cell surface and can lead to excessive complement activation or insufficient regulation, both of which can cause tissue damage.
[0031] As used herein, the phrase "disease mediated by dysregulation of the alternative pathway" refers to the interruption, arrest or impairment of a bodily function, system or organ caused by dysregulation of the alternative pathway. Such diseases would benefit from treatment with the compositions or formulations described herein. In some embodiments, the disease is caused by any abnormality in the ability of the alternative pathway to allow the host to defend itself against pathogens, to clear immune complexes and damaged cells, and for immune regulation. Also included herein are diseases mediated directly or indirectly by dysregulation of one or more components of the alternative pathway or products generated by the alternative pathway.
[0032] As used herein, the term "alternative complement pathway-dependent membrane attack complex assembly" refers to the terminal complex formed as a result of activation of the alternative complement pathway and includes complement components C5, C6, C7, C8 and C9. Assembly of the membrane attack complex (MAC) leads to cell lysis.
[0033] As used herein, the term "alternative pathway-dependent hemolysis" refers to the lysis of red blood cells mediated by the assembly and / or deposition of increased alternative pathway-dependent MAC on red blood cells.
[0034] As used herein, the term "linker" refers to a bond between two elements, e.g., protein domains. The linker may be a covalent bond or a spacer. The term "bond" refers to any type of bond that occurs in a chemical reaction, such as an amide bond or a disulfide bond, or chemical conjugation. A linker may also refer to a moiety (e.g., a polyethylene glycol (PEG) polymer) or an amino acid sequence (e.g., a sequence of 3-200 amino acids, a sequence of 3-150 amino acids, or a sequence of 3-100 amino acids) that occurs between two polypeptides or polypeptide domains to provide space and / or flexibility between the two polypeptides or polypeptide domains. The amino acid spacer may be part of the primary sequence of the polypeptide (e.g., linked to the polypeptides or polypeptide domains that are separated from each other via the polypeptide backbone). The linker may include one or more glycine and serine residues. [Brief description of the drawings]
[0035] [Figure 1] Figure 1 shows biolayer interferometry data obtained using an Octet™ biosensor with a model system in which selected anti-properdin antibodies specifically bind to human properdin. The graph shows the equilibrium dissociation over time. [Diagram 2] Figure 2 shows Biolayer Interferometry data obtained using an Octet™ biosensor with a model system in which selected anti-properdin antibodies showed weak or no binding to mouse properdin. The graph shows the equilibrium dissociation over time. [Diagram 3] Figure 3 shows biolayer interferometry data obtained using an Octet™ biosensor with a model system in which selected anti-properdin antibodies showed specific but weak binding to cynomolgus properdin. The graph shows the equilibrium dissociation over time. [Figure 4]FIG. 4 shows that selected anti-properdin antibodies inhibit the activity of human properdin in an alternative pathway hemolytic assay. [Figure 5A] FIG. 5A shows characterization of selected anti-properdin antibodies by mass spectrometry. [Figure 5B] FIG. 5B shows characterization of selected anti-properdin antibodies by mass spectrometry. [Figure 5C] FIG. 5C shows characterization of selected anti-properdin antibodies by mass spectrometry. [Figure 6A] FIG. 6A shows the binding affinity of selected anti-properdin antibodies to biotinylated properdin using the properdin capture method. [Figure 6B] FIG. 6B shows the binding affinity of selected anti-properdin antibodies to biotinylated properdin using the properdin capture method. [Figure 7] FIG. 7 shows the binding affinity of selected anti-properdin bispecific antibodies to biotinylated properdin using the properdin capture method. [Figure 8A] Figure 8A shows that selected anti-properdin bispecific antibodies inhibit the activity of human properdin and cynomolgus monkey properdin in the alternative pathway hemolytic assay. As a control, anti-properdin antibodies were used. [Figure 8B] Figure 8B shows that selected anti-properdin bispecific antibodies inhibit the activity of human properdin and cynomolgus monkey properdin in the alternative pathway hemolytic assay. Anti-properdin antibodies were used as controls. [Figure 9A] FIG. 9A shows that selected anti-properdin bispecific antibodies inhibit the activity of human properdin and cynomolgus properdin in an alternative pathway hemolytic assay. [Figure 9B] FIG. 9B shows that selected anti-properdin bispecific antibodies inhibit the activity of human properdin and cynomolgus properdin in an alternative pathway hemolytic assay. [Figure 10A] FIG. 10A shows the binding affinity of selected anti-properdin bispecific antibodies to biotinylated properdin using the properdin capture method. [Figure 10B] FIG. 10B shows the binding affinity of selected anti-properdin bispecific antibodies to biotinylated properdin using the properdin capture method. [Figure 11A] FIG. 11A shows the binding affinity of selected anti-properdin bispecific antibodies to biotinylated properdin using the properdin capture method. [Figure 11B] FIG. 11B shows the binding affinity of selected anti-properdin bispecific antibodies to biotinylated properdin using the properdin capture method. [Figure 12A] FIG. 12A shows the binding affinity of selected anti-properdin bispecific antibodies to biotinylated properdin using the properdin capture method. [Figure 12B] FIG. 12B shows the binding affinity of selected anti-properdin bispecific antibodies to biotinylated properdin using the properdin capture method. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0036] Properdin is a positive regulator of the alternative pathway. Described herein is a novel monovalent antibody that binds to a single properdin molecule and is useful for treating diseases mediated by dysregulation of the alternative pathway. Described herein is the discovery that the immune complex formed by the binding of a bivalent antibody to multiple properdin multimers is toxic as a therapeutic agent for inhibiting the abnormal activation of the alternative pathway. The monovalent antibody described herein has a 1:1 binding ratio to properdin and by design cannot form antibody / properdin aggregates containing multiple properdin multimers, which is advantageous over bivalent and multivalent antibodies.
[0037] Described below are monovalent antibodies or antibody fragments that can be administered to patients with diseases mediated by dysregulation of the alternative pathway.
[0038] Anti-properdin antibody Described herein are monovalent anti-properdin antibodies, antibody derivatives (e.g., modified, humaneered, chimeric, substituted, humanized, etc.) and antibody fragments thereof that inhibit properdin, a positive regulator of the alternative pathway of complement, and subsequently destabilize the C3 and C5 convertase complexes. The antibodies described herein can, for example, inhibit properdin from binding to C3b, C3Bb, and C3bBb. Inhibiting properdin leads to a decrease in alternative pathway complement activation. This indicates therapeutic benefit for patients with diseases of alternative pathway dysregulation in which the alternative pathway is overactivated.
[0039] The anti-properdin antibodies described herein can be produced by using full-length properdin, properdin polypeptides and / or by using antigenic properdin epitope-containing peptides, such as fragments of properdin polypeptides. Properdin peptides and polypeptides can be isolated and used to produce antibodies as natural polypeptides, recombinant polypeptides or synthetic recombinant polypeptides. Any antigen useful for producing anti-properdin antibodies can be used to produce monovalent antibodies. Suitable monovalent antibody formats and methods for their production are known in the art (e.g., WO2007 / 048037 and WO2007 / 059782, the contents of which are incorporated herein in their entirety).
[0040] Anti-properdin antibodies may be monoclonal or may be derived from monoclonal antibodies. Suitable monoclonal antibodies against a selected antigen may be prepared according to known techniques ("Monoclonal Antibodies: A manual of techniques," Zola (CRC Press, 1988); "Monoclonal Hybridoma Antibodies: Techniques and Applications," Hurrell (CRC Press, 1982)). , the contents of which are incorporated herein by reference in their entirety.
[0041] In other embodiments, the antibody is HH The antibody may be a single domain antibody, such as V. cerevisiae, ... HH A domain is a stable polypeptide that is characterized by the complete antigen-binding capacity of the original heavy chain antibody. HH The domains possess unique structural and functional properties, combining the advantages of conventional antibodies (high target specificity, high target affinity, low inherent toxicity) with important features of small molecule drugs (ability to inhibit enzymes and access receptor clefts). Moreover, they are stable, may be administered by means other than injection, are easy to manufacture, and can be humanized (U.S. Pat. Nos. 5,840,526, 5,874,541, 6,005,079, 6,765,087, EP 1589107, WO97 / 34103, WO97 / 49805, U.S. Pat. Nos. 5,800,988, 5,874,541, 6,015,695, the contents of each of which are incorporated herein in their entirety).
[0042] In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0043] QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAIGWNGEGIYYADSVKGRFTISRDNAKNTGYLQMNSLKPEDTAVYYCAADSEGVVPGFPIAYWGQGTQVTVSG (SEQ ID NO: 71) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0044] QVQLVESGGGLVQPGGSLRLSCAASGFPLNSYAIGWFRQAPGKEREGVSCISVSDDSTYYTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAVDSAPLYGDYVCKPLENEYDFWGQGTQVTVSG (SEQ ID NO: 72) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0045] QVQLVESGGGLVQAGGSLXLSCAASGSDRRINGMGWYRHPPGKQRELVAAITSGGSTNYADSVKGRFTISTNNANNMMYLQMNSLKPEDTAVYYCAIDEFGTGWLDYCGQGTQVTVSG (SEQ ID NO: 73) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0046] QVQLVESGGGLVQPGGSLRLSCAASGRPFSSYAMGWFRQAPGKEREIVAGLSWSGGNVYYADSVKGRFTISRDNAKNTGDLQMNSLKPEDTAVYYCAIGPKLTTGPTAYRYWGQGTQVTVSS (SEQ ID NO: 74) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0047] QVQLVESGGGLVQPGGSLRLSCATSGGTFSSYAMGWFRQAPGKEREFVAAITWNGSNRYYADSVKGRFTISRDNAKSTVYLQMNSLKPEDTAVYYCAAEHSTRYSGFYYYTRGETYHYWGQGTQVTVSG (SEQ ID NO: 75) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0048] QVQLVESGGGLVQAGGSLRLSCAASGRTFSTLGMGWFRQAPGKERQFVAAINWSGSSTYYANSVKGRFTISRDNAQSTMYLQMNSLKPEDTAVYYCAADLDSRYSAYYYYSDESQYDYWGQGTLVTVSG (SEQ ID NO: 76) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0049] QVQVVESGGGLVQPGGSLSLSCAASGRTFSSYAMGWFRQAPGKEREFVAAITWDGANIYYADSVKGRFTLSRDNAENTVWLQLNSLKPEDTAVYYCAAAESGRYSGRDYYSAPGVYLYWGQGTLVTVSG (SEQ ID NO: 77) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0050] QVQLVESGGGLVQAGGSLRLSCAASGSIFDINAMGWYRQAPGKQRELVADITSSGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYTCAAESIRESQNRHQLGYMGPLYDYWGQGTQVTVSG (SEQ ID NO: 78) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0051] QVQLIESGGGLVQAGDSLRLSCAASEGTFSRFAMGWFRQAPGKEREFVAAINWSGGITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTADYYCAAETTTRYSGYYYYEDNKSYDYWGQGTLVTVSG (SEQ ID NO: 79) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0052] QVQVVESGGGLRQTGGSLRLSCTASGRIFEVNMMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDSAKNTVTLQMNSLKSEDTAVYYCNALQYDRYGGAEYWGQGTQVTVSS (SEQ ID NO: 58) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0053] QVLLEESGGGLERTGGSLRLSCAASGSIFSVNSMTWYRQAPGKRREFLGTITEEGRTNYADSVKGRFTISRDNAKNTMYLQMNSLKPEDTAVYYCYANLISSEDRTFGVWGQGTQVTVSS (SEQ ID NO: 80) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0054] QVHLVESGGGLVQAGGSLRLSCTASGGTVGDYAVGWFRQAPGKERELIGVVSRLGARTGYADSVLGRFTISRDDVKNTVFLQMDSVKPEDTAVYYCAARRDYSFEVVPYDYWGQGTQVTVSG (SEQ ID NO: 81) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0055] QVQMVESGGGLVQAGGSLRLSCAASGLTNRIRIMGWYRQAPGKLRELVATITNDGSTHYADSVKGRFTISTDNAKNTVFLQMNSLKPEDTAVYICNVGENWGPAYWGQGTQVTVSG (SEQ ID NO: 82) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0056] QVQLVESGGGLVQPGGSLRLSCAASGFPLNSYAIGWFRQAPGKEREGVSCISVSDDSTYYTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAVDSAPLYGDYVCKPLENEYDFWGQGTQVTVSG (SEQ ID NO: 72) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0057] QVRLTESGGGLVQYGTNLTLTCVASGLISTRNKMGWFRRRSGGQREFVASSTVLSDDVIQDDIAETVKGRFAVARNDYKNILYLQMTAVKPEDTGFYWCASGTSLFGASRREDDFNAWGVGTQVTVSA (SEQ ID NO: 83) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0058] QVQLAESGGGLVQAGDSLKLSCTASGRIFEVNMMAWYRQAPGKDRELVAEISRVGTTTYADSVKGRFTISRDSAKNTVTLQMNSLKSEDTAVYYCNALQYSRYGGAEYWGQGTQVTVSG (SEQ ID NO: 59) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0059] EVQLVESGGGLVQPGGSLRLSCAASGFTFGSADMSWVRQAPGKGPEWVSAINSNGGSTYYAASVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCAQGNWYTEEYHYWGQGTLVTVSG (SEQ ID NO: 84) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0060] QVRLVESGGGLVQAGDSLRLSCAASGRTLSSYAMGWFRQAPGKEREFVAATTWRDTSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAAYYCAAEEPSKYSGRDYYMMGDSYDYWGQGTQVTVSS (SEQ ID NO: 85) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0061] EVQLVESGGGLVQPGGSLRLSCAASGFTFGSADMSWVRQAPGKGPEWVSAINSNGGSTYYAASVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCAQGNWYTEEYHYWGQGTQVTVSG (SEQ ID NO: 86) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0062] QVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMAWFRQAPGKEREFVASISGSGDSRYYADSVKGRFTISRDNAKNTVYLQTNSPKPEDTAVYYCAAVLPTRYSGFYYYSDGTQYHYWGQGTQVTVSS (SEQ ID NO: 87) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0063] QVNLVESGGGSVQAGGSLRLSCAASENINVINDMGWYRQAPGKQRELVAVITGHDNINYADSATGRFTISTYTWNTENLQMNMLKPEDTAVYYCNADITYANGRFNDWGQGTQVTVSS (SEQ ID NO: 88) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0064] QVHLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQPPGKEREFVAAITWSGSSIYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAEETSKYSGSYYYMMGDSYDYWGQGTQVTVSG (SEQ ID NO: 89) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0065] QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAVPWTYGSKYYADSVKGRFTISRDDAKNTVYLQMNNLKPEDTAVYYCAADSSAGYYSGFDYYSAATPYDLWGQGTQVTVSG (SEQ ID NO: 90) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0066] QVQLVESGGGLVQPGGSLRLSCAASGSDYYAIGWFRQAPGKEREGVSCMSRTDGSTYYADSVKDRFTISRDYAKNTVYLQMNSLKPEDTAVYYCGLDRSYPTGGISCLFGDFGSWGQGTQVTVSG (SEQ ID NO: 91) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0067] QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYNMGWFRQRHGNEREFVATISWSGRSTYYADSVKGRFAISRDNANTTVYLQMNSLKPEDSAVYYCAASTRGWYGTQEDDYNFWGQGTQVTVSG (SEQ ID NO: 92) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0068] QVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSG (SEQ ID NO: 60) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0069] QVQLVESGGGLVQAGGSLRLSCAASGGTFSSYSMGWFRQAPGKEREFVAAITWNGVSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPTDTAVYYCAAEITTRYSGFYYYEDNKSYDYWGQGTQVTVSS (SEQ ID NO: 93) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0070] QVQLVESGGGLRQTGESLRLSCTASGRIFEVNMMAWYRQAPGKQRELVAEISRVGTTTYADSVKGRFTISRDSAKNTVTLQMNSLKSEDTAVYYCNALQYDRYGGAEYWGQGTQVTVSG (SEQ ID NO: 61) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0071] EVQLVESGGGLVQPGGSLRLSCAASGFTLDYYAIGWFRQAPGKEREGVSCISRTDGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAVDDSYPTGGISCLFGHFGSWGQGTQVTVSS (SEQ ID NO: 94) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0072] QVQLVESGGGLVQAGDSLRLSCAASGFTFSSYAMGWFRQAPGKEREFVAAITWSGVSTYYADSVKGRFTISRDNAKNRVYLQMNSLKPEDTAVYSCAADGSGRYSGMEYYNRDWVYDYWGQGTQVTVSS (SEQ ID NO: 95) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0073] QVHMVESGGGLVQAGGSLRFSCAASGNIFTISTLDWYRQAPGEQRELVATLTPDGITDYAGSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNAWRYSDDYRGRVDYWGQGTQVTVSG (SEQ ID NO: 96) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0074] QVQLIESGGGLVQEGASLRLSCAGSGPMFSRLAVGWFRQAPGKEREFVAVINWSGSADFYTNSVKGRFTISRDNAKNTVYLEMNTLKPEDSAVYYCAADQNPLTLRTGVRDVGRQWGQGTEVTVSS (SEQ ID NO: 97) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0075] QVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAITWRGASTYYADPVKGRFTISRDNAKNTVYLQMSSLKPEDTAVYYCAAEEPSYYSGSYYYMMGDSYNYWGQGTQVTVSG (SEQ ID NO: 98) In some embodiments, the antibody or antibody fragment thereof comprises the following sequence as its heavy chain variable domain:
[0076] QVQLVESGGGLVQAGGSLRLSCTASGRTFSNYAMGWFRQAPGKEREFLAAISRSGESTNYATFVKGRFTIARDNAKNTVSLQMNSLKPEDTAVYFCAAKVAVLVSTTYNSQYDYWGQGTQVTVSS (SEQ ID NO: 99) The anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs:
[0077] a. CDR-H1 having the amino acid sequence GRIFEVNMMA (SEQ ID NO:9) b. CDR-H2 having the amino acid sequence RVGTTVYADSVKG (SEQ ID NO:12) c. CDR-H3 having the amino acid sequence LQYDRYGGAEY (SEQ ID NO: 13) Additional anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs:
[0078] a. CDR-H1 having the amino acid sequence GRIFEVNMMA (SEQ ID NO:9) b. CDR-H2 having the amino acid sequence RVGTTTYADSVKG (SEQ ID NO: 15) c. CDR-H3 having the amino acid sequence LQYSRYGGAEY (SEQ ID NO: 14) Additional anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs:
[0079] a. CDR-H1 having the amino acid sequence GRIFEVNMMA (SEQ ID NO:9) b. CDR-H2 having the amino acid sequence RVGTTTYADSVKG (SEQ ID NO: 15) c. CDR-H3 having the amino acid sequence LQYDRYGGAEY (SEQ ID NO: 13) Additional anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs:
[0080] a. CDR-H1 having the amino acid sequence GRISSIIHMA (SEQ ID NO: 16) b. CDR-H2 having the amino acid sequence RVGTTVYADSVKG (SEQ ID NO:12) c. CDR-H3 having the amino acid sequence LQYEKHGGADY (SEQ ID NO: 17) Humanized Camelid V HH Polypeptides are taught, for example, in WO004 / 041862, the teachings of which are incorporated herein in their entirety. HH It will be understood by those skilled in the art that naturally occurring camelid antibody single variable domain polypeptides can be modified (e.g., amino acid substitutions at positions 45 and 103 (W004 / 041862)) to produce polypeptides. HH (Greenberg, A. et al., Nature, 374:168-73, 1995; U.S. Patent Application Publication No. 20050043519).
[0081] Further anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs (eg, to construct scFvs or dAbs):
[0082] a) CDR-H1 having the amino acid sequence GYIFTNYPIH (SEQ ID NO: 18) b) CDR-H2 having the amino acid sequence FIDPGGGYDEPDERFRD (SEQ ID NO: 19) c) CDR-H3 having the amino acid sequence RGGGYYLDY (SEQ ID NO: 20) d) CDR-L1 having the amino acid sequence RASQDISFFLN (SEQ ID NO: 21) e) CDR-L2 having the amino acid sequence YTSRYHS (SEQ ID NO: 22) f) CDR-L3 having the amino acid sequence QHGNTLPWT (SEQ ID NO: 23) Further anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs (eg, to construct an scFv):
[0083] a) CDR-H1 having the amino acid sequence GFSLTTYGVH (SEQ ID NO: 24) b) CDR-H2 having the amino acid sequence VIWSGGDTDYNASFIS (SEQ ID NO: 25) c) CDR-H3 having the amino acid sequence NKDYYTNYDFTMDY (SEQ ID NO: 26) d) CDR-L1 having the amino acid sequence KSSQSVLYSSNQKNFLA (SEQ ID NO: 27) e) CDR-L2 having the amino acid sequence WASTRES (SEQ ID NO:28) f) CDR-L3 having the amino acid sequence HQYLSSYT (SEQ ID NO: 29) Further anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs (eg, to construct an scFv):
[0084] a) CDR-H1 having the amino acid sequence GYTFIDYWIE (SEQ ID NO: 30) b) CDR-H2 having the amino acid sequence EIFPGSGTINHNEKFKD (SEQ ID NO: 31) c) CDR-H3 having the amino acid sequence EGLDY (SEQ ID NO: 32) d) CDR-L1 having the amino acid sequence SASSSVSYIY (SEQ ID NO: 33) e) CDR-L2 having the amino acid sequence DTSTLAS (SEQ ID NO: 34) f) CDR-L3 having the amino acid sequence QQWSRNPFT (SEQ ID NO: 35) Further anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs (eg, to construct an scFv):
[0085] a) CDR-H1 having the amino acid sequence GFSLTSYGVH (SEQ ID NO: 36) b) CDR-H2 having the amino acid sequence VIWSGGSTDYNAAFIS (SEQ ID NO: 37) c) CDR-H3 having the amino acid sequence NKDFYSNYDYTMDY (SEQ ID NO: 38) d) CDR-L1 having the amino acid sequence KSSQSVLYSSNQKNFLA (SEQ ID NO: 27) e) CDR-L2 having the amino acid sequence WASTRES (SEQ ID NO:28) f) CDR-L3 having the amino acid sequence HQYLSSYT (SEQ ID NO: 29) Further anti-properdin antibodies, antibody derivatives and fragments thereof disclosed herein include those having one or more or all of the following CDRs (eg, to construct an scFv):
[0086] a) CDR-H1 having the amino acid sequence GYTXTAYGIN (SEQ ID NO: 39) b) CDR-H2 having the amino acid sequence YIYIGNGYTDYNEKFKG (SEQ ID NO: 40) c) CDR-H3 having the amino acid sequence SGWDEDYAMDF (SEQ ID NO: 41) d) CDR-L1 having the amino acid sequence RASENIYSYLA (SEQ ID NO: 42) e) CDR-L2 having the amino acid sequence HAKTLAE (SEQ ID NO: 43) f) CDR-L3 having the amino acid sequence QHHYGPPPT (SEQ ID NO: 44) In some embodiments, the antibody or antibody fragment thereof comprises the sequence:
[0087] LEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSSRKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 53) In some embodiments, the antibody or antibody fragment thereof comprises the sequence:
[0088] LEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSSPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 54) In some embodiments, the antibody or antibody fragment thereof comprises the following light chain and heavy chain sequences:
[0089] DIQMTQSPSSLSASVGDRVTITCRASQDISFFLNWYQQKPGKAPKLLIYYTSRYHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHGNTLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 56) QVQLVQSGAEVKKPGASVKVSCKASGYIFTNYPIHWVRQAPGQGLEWMGIDPGGGYDEPDERFRDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARRGGGYYLDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 57) In some embodiments, the antibody or antibody fragment thereof comprises the sequence:
[0090] LEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS (SEQ ID NO: 55) In some embodiments, the antibody or antibody fragment thereof comprises the sequence:
[0091] EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGSGGGGSGGGGSLEVQLVESGGGLVQAGGSLRLSCAASGRISSIIHMAWYRQAPGKQRELVAEISRVGTTVYADSVKGRFTISRDDAKNTVTLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTQVTVSS (SEQ ID NO: 45)
[0092] Anti-properdin antibody fragments and derivatives Some naturally occurring antibodies are bivalent because they contain two antigen-binding domains. Many smaller antigen-binding fragments of naturally occurring antibodies have been identified after protease digestion. These fragments include, for example, "Fab fragments" (V L -C L -C H 1-V H ), "Fab' fragment" (Fab with the heavy chain hinge region) and "F(ab')2 fragment" (a dimer of Fab' linked by the heavy chain hinge region). For example, V linked by a synthetic peptide linker L and V HA fragment called "single chain Fv" (variable fragment), or "scFv" (V L -Linker-V H Recombinant methods have been used to generate smaller antibody fragments such as Fab, Fab' and scFv fragments, each of which contains one V H / V L Since they contain only one dimer-containing antigen-binding domain, they are monovalent for antigen binding. An even smaller monovalent antibody fragment is the dAb, which specifically binds to an antigen alone, i.e., the complementary V L Domain or V H V that does not require a domain H or V L A dAb contains only one immunoglobulin variable domain, such as the V domain. A dAb binds to an antigen independently of other V domains. However, there are cases where no other domains are required for antigen binding by a dAb, i.e., the dAb does not bind to other V domains. H Domain or V L In cases where antigen binding is independent of the domain, other V H Domain or V L dAbs may also exist in homo- or heteromultimers containing domains.
[0093] Linker In the present invention, linker is used to describe a link or connection between polypeptides or protein domains and / or related non-protein moieties. In some embodiments, a linker is a link or connection between at least two polypeptide constructs, such that the two polypeptide constructs are tandemly linked to each other (e.g., a monovalent antibody linked to a second polypeptide or monovalent antibody). A linker can connect the N-terminus or C-terminus of one antibody construct to the N-terminus or C-terminus of a second polypeptide construct.
[0094] The linker can be a simple covalent bond such as a peptide bond, a synthetic polymer such as a polyethylene glycol (PEG) polymer, or any kind of bond that occurs by some chemical reaction such as chemical conjugation. When the linker is a peptide bond, the carboxylic acid group at the C-terminus of one protein domain can react with the amino group at the N-terminus of another protein domain in a condensation reaction to form a peptide bond. Specifically, the peptide bond can be formed by synthetic means by conventional organic chemical reactions well known in the art, or by natural production from a host cell. In the latter case, the polynucleotide sequence encoding the DNA sequences of both proteins, such as two antibody constructs arranged in tandem, can be directly transcribed and translated into a continuous polypeptide encoding both proteins by the necessary molecular machinery in the host cell, such as DNA polymerase and ribosomes.
[0095] When the linker is a synthetic polymer, such as a PEG polymer, both ends of the polymer can be functionalized with reactive chemical groups for reaction with the terminal amino acids at the connecting ends of the two proteins.
[0096] When the linker (except for the peptide bond mentioned above) is made by chemical reaction, for example, a chemical functional group such as amine, carboxylic acid, ester, azide, or other functional group commonly used in the art can be attached to the C-terminus of one protein and the N-terminus of another protein by chemical synthesis, respectively. The two functional groups are then reacted via chemical synthesis means to form a chemical bond to link the two proteins. Such chemical conjugation procedures are routine for those skilled in the art.
[0097] In the present invention, the linker between two peptide constructs may be an amino acid linker comprising 1-200 (e.g., 1-4, 1-10, 1-20, 1-30, 1-40, 2-10, 2-12, 2-16, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200) amino acids. Suitable peptide linkers are known in the art and include, for example, peptide linkers comprising flexible amino acid residues such as glycine and serine. In some embodiments, the linker can include a single motif or multiple different or repeated motifs of GS, GGS, GGGGS (SEQ ID NO:1), GGSG (SEQ ID NO:2), or SGGG (SEQ ID NO:3). Exemplary motifs are (GS) n , ( G4D) n , (G4E) n , (G4A) n where n=1, 2, 3, 4, 5 or 6 or more and combinations thereof. Other linkers include the sequences GGGGD (SEQ ID NO: 63), GGGGE (SEQ ID NO: 64) and GGGGA (SEQ ID NO: 100). Linkers can be designed by combining these various motifs. Such linkers include GGGGSGGGSGGGGS (SEQ ID NO: 4), GGGGDGGGGDGGGG (SEQ ID NO: 5), GGGGEGGGGEGGGG (SEQ ID NO: 6) and GGGAGGGGAGGGGGS (SEQ ID NO: 101).
[0098] Bispecific constructs The invention also features bispecific constructs in which two antigen-binding polypeptides are linked (e.g., by a linker, such as any one of SEQ ID NOs: 1-6, 63-64, and 100-101). Such bispecific constructs may include an anti-properdin binding polypeptide (such as a monovalent antibody) connected to a second polypeptide (such as a second monovalent antibody) by a linker. The second polypeptide may increase the in vivo stability of the bispecific construct. In some embodiments, the second polypeptide is an albumin binding molecule, an albumin binding peptide, or an anti-albumin antibody (such as a monovalent antibody), or modified forms thereof. Albumin binding peptides are known in the art and described, for example, in WO2007 / 106120 (see Tables 1 to 9) and Dennis et al., 2002, J Biol. Chem. 277: 35035-35043, the disclosures of which are incorporated herein by reference.
[0099] In some embodiments, the second polypeptide is an Fc domain, which increases the in vivo stability of the construct.
[0100] Exemplary bispecific constructs are shown in Example 5 below.
[0101] In some embodiments, a monovalent anti-properdin antibody is linked to a monovalent anti-albumin antibody. The monovalent anti-properdin antibody may be linked by its N-terminus or C-terminus to the N-terminus or C-terminus of the monovalent anti-albumin antibody.
[0102] The monovalent anti-properdin antibody may be linked at its N-terminus or C-terminus to the monovalent anti-albumin antibody using a linker having any one of the amino acid sequences of SEQ ID NOs: 1 to 6, 63 to 64, and 100 to 101.
[0103] In some embodiments, a monovalent anti-properdin antibody comprising the amino acid sequence of SEQ ID NO: 58 is linked to a monovalent anti-albumin antibody. The monovalent anti-properdin antibody comprising the sequence of SEQ ID NO: 58 may be linked by its N-terminus or C-terminus to the N-terminus or C-terminus of the monovalent anti-albumin antibody using a linker comprising any one of the amino acid sequences of SEQ ID NOs: 1-6, 63-64, and 100-101.
[0104] In some embodiments, a monovalent anti-properdin antibody comprising the amino acid sequence of SEQ ID NO: 59 is linked to a monovalent anti-albumin antibody. The monovalent anti-properdin antibody comprising the sequence of SEQ ID NO: 59 may be linked by its N-terminus or C-terminus to the N-terminus or C-terminus of the monovalent anti-albumin antibody using a linker comprising any one of the amino acid sequences of SEQ ID NOs: 1-6, 63-64, and 100-101.
[0105] In some embodiments, a monovalent anti-properdin antibody comprising the amino acid sequence of SEQ ID NO: 60 is linked to a monovalent anti-albumin antibody. The monovalent anti-properdin antibody comprising the sequence of SEQ ID NO: 60 may be linked by its N-terminus or C-terminus to the N-terminus or C-terminus of the monovalent anti-albumin antibody using a linker comprising any one of the amino acid sequences of SEQ ID NOs: 1-6, 63-64, and 100-101.
[0106] In some embodiments, a monovalent anti-properdin antibody comprising the amino acid sequence of SEQ ID NO: 61 is linked to a monovalent anti-albumin antibody. The monovalent anti-properdin antibody comprising the sequence of SEQ ID NO: 61 may be linked at its N-terminus or C-terminus to the monovalent anti-albumin antibody using a linker comprising any one of the amino acid sequences of SEQ ID NOs: 1-6, 63-64, and 100-101.
[0107] In some embodiments, a monovalent anti-properdin antibody comprising the amino acid sequence of SEQ ID NO:60 is linked at its N-terminus to a monovalent anti-albumin antibody using a linker comprising the sequence of SEQ ID NO:4.
[0108] In some embodiments, a monovalent anti-properdin antibody comprising the amino acid sequence of SEQ ID NO:60 is linked at its N-terminus to a monovalent anti-albumin antibody using a linker comprising the sequence of SEQ ID NO:5.
[0109] In some embodiments, a monovalent anti-properdin antibody comprising the amino acid sequence of SEQ ID NO:60 is linked at its N-terminus to a monovalent anti-albumin antibody using a linker comprising the sequence of SEQ ID NO:6.
[0110] In some embodiments, the bispecific construct comprises the amino acid sequence of any one of SEQ ID NOs: 45-55 and 62.
[0111] In some embodiments, the monovalent anti-properdin antibody is linked at its N-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:1.
[0112] In some embodiments, the monovalent anti-properdin antibody is linked at its N-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:2.
[0113] In some embodiments, the monovalent anti-properdin antibody is linked at its N-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:3.
[0114] In some embodiments, the monovalent anti-properdin antibody is linked at its N-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:4.
[0115] In some embodiments, the monovalent anti-properdin antibody is linked at its N-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:5.
[0116] In some embodiments, the monovalent anti-properdin antibody is linked at its N-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:6.
[0117] In some embodiments, the monovalent anti-properdin antibody is linked at its N-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:63.
[0118] In some embodiments, the monovalent anti-properdin antibody is linked at its N-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:64.
[0119] In some embodiments, the monovalent anti-properdin antibody is linked at its C-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:1.
[0120] In some embodiments, the monovalent anti-properdin antibody is linked at its C-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:2.
[0121] In some embodiments, the monovalent anti-properdin antibody is linked at its C-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:3.
[0122] In some embodiments, the monovalent anti-properdin antibody is linked at its C-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:4.
[0123] In some embodiments, the monovalent anti-properdin antibody is linked at its C-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:5.
[0124] In some embodiments, the monovalent anti-properdin antibody is linked at its C-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:6.
[0125] In some embodiments, the monovalent anti-properdin antibody is linked at its C-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:63.
[0126] In some embodiments, the monovalent anti-properdin antibody is linked at its C-terminus to a monovalent anti-albumin antibody with a linker comprising the sequence of SEQ ID NO:64.
[0127] Generation of single domain antibodies In one embodiment, the compositions and methods include H ,For example, V HH ) or the light chain domain (V L Thus, one means of producing a monovalent single domain antibody specific for properdin is to use, for example, a V domain of heavy and light chain gene sequences isolated from a hybridoma (e.g., a murine hybridoma) expressing an anti-properdin monoclonal antibody. H Area and V L The aim is to amplify and express the region. H Domains and V L The boundaries of the domains are described, for example, in Kabat et al. (Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1991). To design PCR primers to amplify V domains from heavy or light chain coding sequences encoding antibodies known to bind properdin, the V domains of the heavy and light chain genes are amplified. H Domains and V L The domain boundary information is used. The amplified V domains are inserted into a suitable expression vector, such as pHEN-1 (Hoogenboom, H. et al., Nucleic Acids Res., 19:4133-7, 1991), and the V domains in the scFv are expressed as H and V LThe polypeptides are expressed as fusions of properdin or in other suitable monovalent formats. The resulting polypeptides can be screened for high affinity monovalent binding to properdin. Screening for binding can be performed by methods known in the art. Single domain antibodies can be produced using methods known in the art (WO2005118642; Ward, E. et al., Nature, 341:544-6, 1989; Holt, L. et al., Trends Biotechnol., 21:484-90, 2003). Each light chain domain can be either of the kappa or lambda subgroup. V H Domains and V L Methods for isolating domains have been described in the art (EP0368684).
[0128] In one embodiment, the single domain antibody is derived from a human, a humanized rodent, a camelid or a shark. Such single domain antibodies can be optionally humanized. Humanization of camelid single domain antibodies requires the introduction and mutagenesis of a limited number of amino acids within a single polypeptide chain. This is in contrast to humanization of scFv, Fab, (Fab')2 and IgG, which requires the introduction of amino acid changes in two chains, light and heavy, preserving the assembly of both chains. In some embodiments, single domain antibodies are derived from V HH In some embodiments, the V HH The domain is the V of a naturally occurring heavy chain antibody against properdin. HH Such a V HHThe sequence can be determined, for example, by immunizing a camelid species appropriately with properdin (i.e. eliciting an immune response against properdin and / or heavy chain antibodies) using any suitable technique known in the art (e.g. one may clone genes encoding the single domain antibody by single cell PCR or one may immortalize B cells encoding the single domain antibody by EBV transformation or fusion to an immortalized cell line), obtaining a suitable biological sample from said camelid (such as a blood sample, serum sample or B cell sample), starting with said sample, and isolating the V against properdin. HH The sequences can be generated by:
[0129] Alternatively, such naturally occurring V HH The domains can be, for example, screened for inclusion in camelid V sequences using one or more screening techniques known in the art. HH Naive libraries of sequences can be obtained from such libraries by screening with properdin or at least one portion, fragment, antigenic determinant or epitope thereof (WO99 / 37681, WO01 / 90190, WO03 / 025020 and WO03 / 035694). Alternatively, naive V sequences can be generated by techniques such as random mutagenesis and / or CDR shuffling. HH V obtained from the library HH Library, Naive V HH Improved synthetic or semi-synthetic libraries derived from the library may also be used (WO00 / 43507). HH Libraries are constructed and expressed on phages after infection with helper phage. After several rounds of biopanning, single domain antibodies against human properdin can be isolated and efficiently expressed.
[0130] To facilitate screening, HH Fragment or V HHLibraries of fusion proteins containing the fragments can be displayed on phages, phagemids, ribosomes or suitable microorganisms such as yeast. HH Fragment or V HH Suitable methods, techniques and host organisms for displaying and screening (sets, collections or libraries) of fusion proteins comprising fragments are known in the art (WO03 / 054016; Hoogenboom, H., Nat. Biotechnol., 23:1105-16, 2005).
[0131] In another embodiment, V HH Fragment sequence or V HH A method for producing a fusion protein comprising a fragment sequence includes at least the steps of: a) providing a population or sample of cells from a species of camelid expressing immunoglobulin sequences; b) screening the population or sample of cells for (i) cells expressing immunoglobulin sequences capable of binding to and / or having affinity for properdin, (ii) cells expressing heavy chain antibodies; and c) screening the population or sample of cells for (i) cells expressing immunoglobulin sequences capable of binding to and / or having affinity for properdin, (ii) cells expressing heavy chain antibodies. HH or (ii) isolating the V sequence present in the heavy chain antibody from the cell. HH After isolating the nucleic acid sequence encoding the V HH and expressing the domain, to prepare heavy chain antibodies capable of binding to and / or having affinity for properdin, substeps (i) and (ii) can be carried out essentially as one screening step or can be carried out as two separate screening steps in any suitable order.
[0132] The method for generating an amino acid sequence for properdin comprises at least: a) a heavy chain antibody or HH b) providing a set, collection or library of nucleic acid sequences encoding V sequences capable of binding to properdin and / or having affinity for properdin; HHc) screening the set, collection or library of nucleic acid sequences for nucleic acid sequences encoding a fusion protein or heavy chain antibody comprising the V sequence, HH Either express the sequence or HH and expressing a fusion protein comprising the sequence.
[0133] Naturally occurring V H Array or V HH Other suitable methods and techniques for obtaining single domain antibodies and / or nucleic acids encoding same, starting from a sequence, can be used to obtain a monovalent anti-properdin single domain antibody or a nucleic acid encoding same, for example by cloning one or more naturally occurring V sequences (such as one or more framework region (FR) sequences and / or CDR sequences) in a suitable manner to provide a monovalent anti-properdin single domain antibody or a nucleic acid encoding same. HH One or more portions of a sequence, one or more naturally occurring V sequences (such as one or more framework region sequences or CDR sequences), HH It may involve combining one or more portions of a sequence and / or one or more synthetic or semi-synthetic sequences. HH Alternatively, sequences encoding the framework sequences of single domain antibodies may be obtained by polymerase chain reaction (PCR) starting from sequences known in the art and obtained using the methods described herein. Such compositions can be suitably combined (e.g., by PCR assembly using overlapping primers) with sequences encoding the desired CDRs to provide single domain antibodies or antibody fragments fused to regulators of the alternative complement pathway or fragments thereof.
[0134] Generation of antibody fragments Antibody fragments that recognize the same epitope as the parent antibody can be produced by known techniques. For example, antibody fragments can be prepared by proteolytic hydrolysis of the antibody or by expressing DNA encoding the fragment in E. coli. Antibody fragments are antigen-binding portions of antibodies, such as Fab, F(ab')2, and scFVs, which can be obtained by pepsin or papain digestion of whole antibodies by conventional methods or by genetic engineering techniques.
[0135] Antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 100 kDa fragment called F(ab')2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide bonds, to produce 50 kDa Fab' monovalent fragments. Alternatively, an Fc fragment and two monovalent Fab fragments are produced directly by enzymatic cleavage using papain (U.S. Pat. Nos. 4,036,945 and 4,331,647; Nisonoff, A. et al., Arch. Biochem. Biophys., 89:230-44, 1960; Porter, R., Biochem. J., 73:119-26, 1959; Edelman et al., in Methods in Enzymology Vol. I, p.422(Academic Press 1967) and Coligan el al., Current Protocols in Immunology, Vol. 1, p.2.8.1-2.8.10, 2.10.-2.10.4(John Wiley & Sons 1991).
[0136] Other methods of cleaving antibodies may be used, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of the fragments, or other enzymatic, chemical or genetic techniques, so long as the fragment binds to the antigen recognized by the intact antibody.
[0137] Another form of antibody fragment is a peptide encoding a single complementarity determining region (CDR). CDR peptides can be obtained by constructing a gene encoding the CDR of the antibody of interest. Such genes are prepared, for example, by synthesizing the variable region from RNA of antibody-producing cells using the polymerase chain reaction (Larrick, J & Fry, K. METHODS- a companion to Methods in Enzymology Volume: New Techniques in Antibody Generation, 2:106-110, 1991); Courtenay Luck, “Genetic Manipulation of Monoclonal Antibodies,” in Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), p.166-179 (Cambridge University Press 1995), Ward et al., “Genetic Manipulation and Expression of Antibodies,” in Monoclonal Antibodies: Principles And Applications, Birch et al., (eds.), p.137-1 85 (Wiley-Liss, Inc. 1995)).
[0138] Other antibody fragments, such as single domain antibody fragments, are known in the art and can be used in the claimed constructs (Muyldermans, S. et al., Trends Biochem. Sci., 26:230-5, 2001; Yau, K. et al., J. Immunol. Methods, 281:161-75, 2003; Maass, D. et al., J. Immunol. Methods, 324:13-25, 2007). HH has strong antigen-binding ability and is different from conventional VH -V L Camelids can be immunized with a known antigen, such as properdin, and V, which binds to and neutralizes the target antigen, can interact with novel epitopes that are inaccessible to their predecessor. HH can be isolated.
[0139] Screening monovalent antibodies for antigen binding Library screening methods can be used to identify monovalent properdin specific binding antibodies or fragments. Phage display technology provides an approach for selecting antibodies that bind to desired targets (such as human properdin) from a large and diverse repertoire of antibodies (Smith, G., Science, 228:1315-7, 1985; Scott, J. & Smith, G., Science, 249:386-90, 1990; McCafferty, J. et al., Nature, 348:552-4, 1990). These phage antibody libraries are either natural libraries which use rearranged V genes taken from human B cells (Marks, J. et al., J. Mol. Biol., 222:581-97, 1991; Vaughan, T. et al., Nat. Biotechnol., 14:309-14, 1996) or libraries in which germline V gene segments or other antibody polypeptide coding sequences have been "rearranged" in vitro (Hoogenboom, H. & Winter, G., J. Mol. Biol., 227:381-8, 1992; Nissim, A. et al., EMBO J., 13:692-8, 1994; Griffiths, A. et al., EMBO J., 13:3245-60, 1994; de Kruif, J. et al., J. Mol. Biol., 13:3245-60, 1994). 248:97-105, 1995) or synthetic libraries in which synthetic CDRs are integrated into a single rearranged V gene (Barbas, C. et al., Proc. Natl. Acad. Sci. USA, 89:4457-61, 1992). Methods involving genetic display packages (phage display, polysome display, etc.) are suitable for the selection of monovalent properdin-specific antibody constructs, since the display package generally expresses only monovalent fragments and not the entire bivalent antibody.Methods for preparing phage display libraries displaying a variety of antibody fragments are described in the above references, as well as in, for example, US Pat. No. 6,696,245, the contents of which are incorporated herein in their entirety.
[0140] After expressing a repertoire of single domain antibodies on the phage surface, selection is performed by contacting the phage repertoire with an immobilized target antigen (such as properdin), washing to remove unbound phage, and enriching for bound phage. This process is often referred to collectively as "panning". Display libraries (scFv, Fab, (Fab')2 and V HH Monovalent single domain antibodies and antibody fragments that can be expressed in a variety of cell lines (Harrison, J. et al., Meth. Enzymol., 267:83-109, 1996). Alternatively, phage are preselected for expression of properly folded member variants by panning against an immobilized generic ligand (e.g., Protein A or Protein L) to which only folded members bind (WO99 / 20749). This method has the advantage that the proportion of members that are not functional is reduced, thereby increasing the proportion of members that can bind the target antigen. Screening of phage antibody libraries has generally been described, for example, by.
[0141] Screening is typically performed using purified antigen immobilized on a solid support such as a plastic tube or well, or on a chromatography matrix such as Sepharose™ (Pharmacia). Screening or selection can also be performed against complex antigens, such as the surface of a cell (Marks, J. et al., Biotechnology (NY), 11:1145-9, 1993; de Kruif, J. et al., Proc. Natl. Acad. Sci. USA, 92:3938-42, 1995). Alternatively, selection can be performed by binding biotinylated antigen in solution followed by capture with streptavidin-coated beads. HH Coding sequences are known in the art and include camelid V HH It can be used to construct phage display libraries, which can be used to isolate antibody fragments by biopanning techniques known in the art.
[0142] Expression of anti-properdin antibodies Nucleic acid manipulations can be performed with recombinant vectors. As used herein, a "vector" refers to a separate element used to introduce heterologous DNA into cells for expression and / or replication. Methods for selecting or constructing and subsequently using such vectors are known to those of skill in the art. Numerous vectors are publicly available, such as bacterial plasmids, bacteriophages, artificial chromosomes, episomal vectors, etc. Such vectors can also be used for simple cloning and mutagenesis. A vector is selected to accommodate a polypeptide coding sequence of the desired size. A suitable host cell is transformed with the vector after in vitro cloning manipulations. Each vector contains various functional components, generally including a cloning (or "polylinker") site and an origin of replication. An expression vector can further include one or more of an enhancer element, a promoter, a transcriptional termination sequence, and a signal sequence, each located near the cloning site so as to be transcriptionally linked to a gene encoding a polypeptide.
[0143] Both cloning and expression vectors usually contain nucleic acid sequences that allow the vector to replicate in one or more selected host cells. Cloning vectors generally contain sequence elements that allow the vector to replicate independently of the host chromosomal DNA, including origins of replication or autonomously replicating sequences. Such sequences are known from a variety of bacteria, yeast, and viruses.
[0144] In the case of the screened library described herein, the vector can be an expression vector that allows the expression of the polypeptide library member. Selection is done by separately growing and expressing a single clone expressing the polypeptide library member or by using any selection display system. In the case of bacteriophage display, phage or phagemid vectors can be used. Phagemid vectors have an E. coli origin of replication (for double-stranded replication) and a phage origin of replication (for the production of single-stranded DNA).
[0145] Purification and concentration of monovalent antibodies Monovalent antibodies secreted into the periplasmic space or into the bacterial medium are harvested and purified by known methods (Skerra, A. & Pluckthun, A., Science, 240:1038-41, 1988 and Breitling, F. et al. (Gene, 104:147-53, 1991) describe the harvesting of antibody polypeptides from the periplasm and Better, M. et al. (Science, 240:1041-3, (1988) describes recovery from culture supernatant. For some antibody polypeptides, purification can also be achieved by binding to common ligands such as protein A or protein L. Alternatively, variable domains can be expressed using peptide tags such as Myc, HA or 6xHis tags. This method facilitates purification by affinity chromatography. If necessary, monovalent anti-properdin antibodies are concentrated using any of several methods well known in the art, including ultrafiltration, diafiltration and tangential flow filtration. The process of ultrafiltration uses semi-permeable membranes and pressure to separate molecular species based on size and shape. Pressure can be generated by gas pressure or centrifugation. By choosing a molecular weight cutoff smaller than the target antibody (usually 1 / 3 to 1 / 6 the molecular weight of the target polypeptide), the anti-properdin antibody is retained as solvent and small solutes pass through the membrane.
[0146] Pharmaceutical Compositions, Dosages and Administration The antibodies described herein can be incorporated into pharmaceutical compositions suitable for administration to a subject. In general, pharmaceutical compositions include a monovalent anti-properdin antibody, an antibody derivative or fragment thereof, and a pharma- ceutically acceptable carrier. As used herein, a "pharma-ceutically acceptable carrier" includes any and all physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The term "pharma-ceutically acceptable carrier" does not include tissue culture media containing bovine or horse serum. Examples of pharma-ceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, as well as combinations thereof. In many cases, it will be preferable to include an isotonic agent, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable substances include minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody.
[0147] The compositions described herein may take a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (including injection and infusion solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The final form will depend on the intended mode of administration and therapeutic application. Typical compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies. The compositions are, for example, delivered by parenteral injection (intravenous, subcutaneous, intraperitoneal, intramuscular, etc.).
[0148] Therapeutic compositions generally must be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as solutions, microemulsions, dispersions, liposomes or other ordered structures suitable for high drug concentration. Sterile injectable solutions can be prepared by incorporating the required amount of monovalent antiproperdin antagonists in a suitable solvent with one or a combination of the above ingredients as required, followed by filter sterilization. In general, dispersions are prepared by incorporating monovalent antiproperdin antagonists in a sterile vehicle that contains a basic dispersion medium and the other required ingredients listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred preparation methods are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus other desired ingredients from a previously sterile-filtered solution. The proper fluidity of the solution can be maintained, for example, by the use of a coating such as lecithin, the maintenance of the required particle size in the case of dispersions, and the use of surfactants.
[0149] The antibodies described herein can be administered by a variety of methods known in the art, although for many therapeutic applications, the preferred route / method of administration is intravenous injection or infusion. Polypeptides can also be administered by intramuscular or subcutaneous injection.
[0150] As will be appreciated by those skilled in the art, the route and / or method of administration will vary depending on the desired results. In some embodiments, the antibody can be prepared with a carrier that protects the antibody from rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Monovalent single domain antibodies are in some ways suitable for formulation as sustained release formulations due to their small size, i.e., the number of moles per dose can be significantly higher than, for example, full-sized antibodies. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid, etc. can be used. Prolonged absorption of injectable compositions can be achieved by including in the composition an agent that delays absorption, such as monostearates and gelatin. Many methods for preparing such formulations are known to those skilled in the art (e.g., Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978). Methods applicable to the controlled or sustained release of antibodies, such as the monovalent single domain antibodies disclosed herein, are known (such as U.S. Pat. Nos. 6,306,406 and 6,346,274, U.S. Patent Application Nos. US20020182254 and US20020051808, the teachings of which are incorporated herein in their entirety).
[0151] In some embodiments, a monovalent anti-properdin antibody, antibody derivative or fragment thereof can be administered orally, for example, with an inert diluent or an assimilable edible carrier. To administer the compositions described herein by other than parenteral administration, the compound may need to be coated with, or administered with, a material to prevent its inactivation.
[0152] Other active compounds may also be incorporated into the composition. In some embodiments, the monovalent anti-properdin antibody, antibody derivative or fragment thereof is formulated and / or administered together with one or more additional therapeutic agents. For example, the monovalent anti-properdin antibody, antibody derivative or fragment thereof may be formulated and / or administered together with one or more additional antibodies that bind to other targets (e.g., antibodies that bind regulators of the alternative complement pathway). Such combination therapy reduces the dosage of the therapeutic agent administered, thus avoiding potential toxicities or complications associated with various monotherapies. Additionally, the compositions described herein may be formulated or administered together with other therapeutic agents to ameliorate side effects of administering the compositions described herein (e.g., therapeutic agents that minimize the risk of infection in immunocompromised environments, such as antibacterial, antifungal and antiviral agents).
[0153] A pharmaceutical composition may contain a "therapeutically effective amount" or a "prophylactically effective amount" of a monovalent anti-properdin antagonist (e.g., an antibody or derivative or fragment thereof). A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of an antibody may vary according to factors such as the disease state, age, sex, and weight of the individual and the ability of the monovalent anti-properdin antagonist to elicit a desired response in the individual. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. In some embodiments, a prophylactic dose is used in subjects prior to or at an earlier stage of disease, where the prophylactically effective amount is less than the therapeutically effective amount.
[0154] Dosage regimens may be adjusted to provide the optimum desired response (e.g., therapeutic or prophylactic response). For example, a single bolus may be administered or several divided doses may be administered over time with proportionally reduced or increased doses depending on the exigencies of the therapeutic situation. Parenteral compositions are advantageously formulated in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form, as used herein, refers to physically discrete units suitable for combined dosage for the mammalian subject to be treated, each containing a predetermined amount of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. It is noted that dosage values may vary with the type and severity of the condition to be alleviated. It is further understood that for a particular subject, a particular dosing regimen may need to be adjusted over time according to the individual need and the professional judgment of the administering clinician.
[0155] A non-limiting range for a therapeutically or prophylactically effective amount of a monovalent anti-properdin antibody, antibody derivative or fragment thereof is 0.1-20 mg / kg, more preferably 1-10 mg / kg. It should be noted that dosage values may vary depending on the type and severity of the condition being alleviated. It should further be understood that for a particular subject, a particular dosing regimen may need to be adjusted over time according to the individual need and the professional judgment of the administering clinician.
[0156] The efficacy of treatment with the monovalent anti-properdin antibodies, antibody derivatives or fragments thereof described herein will be judged by a skilled clinician based on the improvement of one or more symptoms or indicators of the condition or disorder being treated. An improvement of at least 10% (increase or decrease depending on the indicator being measured) in one or more clinical indicators is considered to be "effective treatment", although greater improvements such as 20%, 30%, 40%, 50%, 75%, 90% or even 100% are desirable, and depending on the indicator being measured, greater than 100% improvement (e.g., 2-fold, 3-fold, 10-fold, etc., up to reaching a disease-free state) is desirable.
[0157] Use of monovalent anti-properdin antibodies The compositions described herein can be used in a method of treating a disease or disorder mediated by alternative pathway dysregulation in an individual in need thereof. The method comprises administering to the individual a therapeutically effective amount of a composition comprising a monovalent anti-properdin antibody, antibody derivative or fragment thereof, preferably a composition comprising a single human immunoglobulin variable domain that binds to human properdin. In one embodiment, the monovalent anti-properdin antibody, antibody derivative or fragment thereof described herein is useful for treating a disease mediated by alternative pathway dysregulation by inhibiting activation of the alternative pathway in a mammal, such as a human. Such disorders include systemic lupus erythematosus and lupus nephritis, rheumatoid arthritis, antiphospholipid (aPL) Ab syndrome, glomerulonephritis, paroxysmal nocturnal hemoglobinuria (PNH) syndrome, inflammation, organ transplantation, intestinal and renal I / R disorders, asthma (such as severe asthma), atypical hemolytic uremic syndrome (aHUS), spontaneous fetal loss, DDD, macular degeneration, TTP, IgA nephropathy (Buerger's disease), C3 Glomerulopathy (C3G), Gaucher disease, hidradenitis suppurativa, Behcet's disease, dermatomyositis, severe burns, early sepsis, pneumococcal meningitis, Alzheimer's disease, cancer metastasis, acute respiratory distress syndrome (ARDS), acute lung injury (ACI), transfusion-associated lung injury (TRALI), hemodialysis-related thrombosis, epidermolysis bullosa acquisita (EBA), uveitis, Parkinson's disease, primary biliary atresia, antineutrophil cytoplasmic antibodies These include, but are not limited to, Avascular Thrombocytopenia (ANCA) vasculitis, retinal degeneration, widespread thrombotic microangiopathy (TMA), widespread TMA (APS), hematopoietic stem cell therapy (HSCT) TMA, age-related macular degeneration (AMD), pre-eclampsia, hemolysis, elevated liver enzymes and thrombocytopenia (HELLP) syndrome, multiple sclerosis, antiphospholipid syndrome (APS), relapsing polychondritis, ischemic disorders, stroke, graft versus host disease (GvHD), chronic obstructive pulmonary disease (COPD), emphysema, atherosclerosis, acute coronary syndrome, hemorrhagic shock, dialysis (cardiovascular risk), cardiovascular disease, placental malaria, APS pregnancy loss, membranoproliferative (MP) glomerulonephritis, membranous nephritis, encephalitis, encephalopathy, NMDA receptor antibody encephalitis, malarial hemolytic crisis, abdominal aortic aneurysm (AAA) and thoracoabdominal aortic aneurysm (TAA). EXAMPLES
[0158] The following examples are presented to disclose and explain to one of ordinary skill in the art how the methods claimed herein are performed and how the compounds are prepared. They are intended to be purely illustrative and are not intended to limit the scope of the disclosure.
[0159] Example 1 V HH -His In-Fusion cloning vector construction The pBNJ391 vector was digested with restriction enzymes BstEII and EcoRI to remove the hinge and Fc. The vector was gel purified, resulting in a 1000 bp release product. The annealed oligos UDEC6629 / 6630 were cloned into the pBNJ391 vector using BstEII / EcoRI. The annealed oligos contained the following sequences:
[0160] UDEC 6629 forward primer: GTCACCGTGTCGAGCCATCATCACCATCATCACTGATGAG (SEQ ID NO: 65) UDEC 6630 reverse primer: AATTCTCATCATTTGTCATCATCATCCTTATAGTCGCTCGACACG (SEQ ID NO: 66) The final vector contained a BstEII-6×His-EcoRI site.
[0161] The pNGH0320 vector was then digested with XhoI / BstEII (producing a 13 bp release product) and column purified. HHThe insert was PCR amplified using the phage clone template using forward primer UDEC 6438 (GTCCACTCCCTCGAGGTGCAGCTGGTGGAGTCTGGG, SEQ ID NO: 67) and reverse primer UDEC 6442 (GCTCGACACGGTGACCTGGGTCCCCTGGCCCCA, SEQ ID NO: 68). The PCR product was purified and then used in the In-Fusion protocol for cloning.
[0162] The pBNJ391 vector was digested with BstEII / EcoRI (50 ng / μL). Both complementary oligonucleotides were resuspended in the same molar concentration using TE buffer. Equal volumes of both complementary oligonucleotides (equimolar concentration) were mixed in a 1.5 mL tube. The tube was placed in a standard heat block at 90-95°C for 3-5 minutes. The tube was removed from the instrument and allowed to cool naturally to room temperature (or at least below 30°C). The tube was stored on ice or at 4°C until further use.
[0163] The ligation reaction was formed with a mixture of 1 μL of insert DNA (from the above nucleotides used for ligation into pBNJ391), 2 μL of pBNJ391 (EcoRI / BstEII, 100 ng), 1 μL of 10× ligase buffer (NEB B0202S lot: 11091410), 1 μL of T4 DNA ligase (NEB M0202L lot: 0671502), and 5 μL of water. The ligation reaction was incubated at room temperature for 30 minutes. 1 μL of the ligation reaction was transformed into 30 μL of DH10 chemically competent cells (InVitrogen 18297 lot no. 1552241) and 750 μL of SOC (NEBB9020S lot no. 2971403) was added. The tubes were shaken at 37°C for 1 hour and plated at 10 and 100 μL onto LB carb / glucose plates. Plates were incubated at room temperature over the weekend.
[0164] A colony was picked for PCR to insert 6xHis into pNGH0320. Eight colonies were screened and pBNJ391 was used as a negative control. Isolated colonies were added to 300 μL of TB / Carb / Glucose broth and grown at 37°C. Forward primer UDEC5276 (CATAATAGCTGACAGACTAACAGACTG, SEQ ID NO: 69) and reverse primer UDEC1977 (CGAAACAAGCGCTCATGAGCCCGAAGT, SEQ ID NO: 70) were used. For a 20 μL PCR reaction, DNA from a single colony was added to 10 μL of Go Taq Green PCR Mix, 0.2 μL of forward primer (100 μM), 0.2 μL of reverse primer (100 μM), and 9.6 μL of H2O for a total of 20 μL. PCR conditions were as follows: 95°C for 3 min, 95°C for 20 sec, 50°C for 20 sec, 72°C for 1 min 15 sec. This cycle was repeated 30 times, followed by incubation at 72°C for 5 min and storage at 4°C until further use. 5 μL of PCR product was mixed with 15 μL water and run on a 2% E gel. Two clones matched the expected size. Plasmid maxi prep from an overnight culture with Promega maxi prep kit was used.
[0165] V to pNGH0320 HH Using in-fusion ligation of V HH Anti-properdin V in His-tagged format HH For antibody cloning, V from the Llama anti-properdin library pLNJ with an XhoI site for cloning into pNGH0317 by in-fusion was used. H Use the UDEC 6438-Infusion forward primer and UDEC 6442-Infusion reverse primer for phagemid amplification to generate the V HHInserts were generated. For a 60 μL PCR reaction, add 30 μL of 2x Fusion PCR mix (NEB M0531s lot: 0211412), 1 μL of bacterial culture, 0.1 μL of forward primer UDEC 6438 (100 μM), 0.1 μL of reverse primer UDEC 6442 (100 μM), and 28.8 μL of H2O for a total of 20 μL. PCR conditions were as follows: 98 °C for 3 min, 98 °C for 10 s, 52 °C for 15 s, 72 °C for 30–60 s, followed by 72 °C for 5 min. This cycle was repeated 30 times and kept at 4 °C until further use. 5 μL of PCR product was mixed with 15 μL of water and run on a 2% E gel. All clones matched the predicted size. Clones were pooled from eight reactions and column purified using the PromegaWizard® SV Gel and PCR Clean-Up System according to the manufacturer's instructions. Plasmid maxi preps from overnight cultures using the Promega maxi prep kit were used.
[0166] For insert ligation, a ligation reaction was formed with 2 μL of 5x In-Fusion HD Enzyme Premix (Clontech 639650 lot: 1501713A), 2.5 μL of Vector pNGH0320(XhoI / BstEII) 39.1 ng / L (100 ng), 1 μL of purified PCR fragment (10–200 ng), and 4.5 μL of water. The ligation reaction was incubated at 50 °C for 15 min.
[0167] For transformation, Stellar™ competent cells (Clontech) were thawed in an ice bath immediately prior to use. After thawing, the cells were gently mixed to ensure uniform distribution and 50 μL of competent cells were transferred to a 14 mL round-bottom tube (Falcon tube). 1 μL (less than 5 ng of DNA) was added to the cells. The tube was placed on ice for 30 min. The cells were then heat shocked at 42°C for exactly 45 s. The tube was then placed on ice for 1-2 min. SOC medium was added to a final volume of 500 μL (before use, SOC medium was warmed to 37°C). The tube was incubated at 37°C for 1 h with shaking (160-225 rpm). Then, 10 μL of this solution was plated on an LB plate containing carbenicillin. The plate was incubated overnight at 37°C.
[0168] 24 V in each pool HH Colony PCR screening was performed for colony insertions. A total of 48 clones were selected for each pool. Vector pNGH0320.1 was used as a positive control. Forward primer UDEC5276 and reverse primer UDEC1977 were used. In a 20 μL PCR reaction, DNA from a single colony was added to 10 μL of Go Taq Green PCR Mix, 0.2 μL of forward primer (100 μM), 0.2 μL of reverse primer (100 μM), and 9.6 μL of H2O for a total of 20 μL. PCR conditions were as follows: 95°C for 3 min, 95°C for 20 s, 50°C for 20 s, and 72°C for 1 min 15 s. This cycle was repeated 30 times, followed by 72°C for 5 min and a further hold at 4°C until use. 5 μL of PCR product was mixed with 15 μL of water and run on a 2% E gel. Sequence analysis was performed on all 48 clones.
[0169] Immune-biased Llama V HH Preliminary screening of the phage display library identified 192 V< / em>s that were ELISA positive for properdin binding. HH were identified. 57 V HH were cloned and expressed with a 6x histidine tag. HHwere Octet positive for properdin binding. A summary is shown in Table 1 below.
[0170] [Table 1] Four functional Vs for effective inhibition of alternative pathway-mediated hemolysis HH was found and is shown in Table 2 below.
[0171] [Table 2] Example 2 Anti-properdin V against human properdin HH Antibody binding Figure 1 shows that kinetic binding measurements can be performed on an Octet instrument (ForteBio Inc.). All washing, dilution and measurements are performed in Kinetic buffer (ForteBio catalog 185032) with plates shaking at 1000 rpm. Streptavidin biosensors (Forte Bio catalog: 18-5019 lot: 1405301) were equilibrated with Kinetic buffer for 10 min and then loaded with 50 nm of biotinylated human properdin. In the association phase, selected anti-properdin antibodies or kinetic buffer blank at 10 μg / mL were added to the biosensors preloaded with biotinylated human properdin, respectively. These results show the binding of AB005, AB006, AB007 and AB008 to human properdin.
[0172] Figure 2 shows that kinetic binding measurements can be performed on an Octet instrument (ForteBio Inc.). All washing, dilution and measurements are performed in Kinetic buffer (ForteBio catalog 185032) with plates shaking at 1000 rpm. Streptavidin biosensors (Forte Bio catalog: 18-5019 lot: 1405301) were equilibrated with Kinetic buffer for 10 min and then loaded with 50 nm of biotinylated mouse properdin. In the association phase, selected anti-properdin antibodies or kinetic buffer blank at 10 μg / mL were added to biosensors preloaded with biotinylated human properdin, respectively. These results show weak or no binding of AB005, AB006, AB007 and AB008.
[0173] Figure 3 shows that kinetic binding measurements can be performed on an Octet instrument (ForteBio Inc.). All washing, dilution and measurements are performed in Kinetic buffer (ForteBio catalog 185032) with plates shaking at 1000 rpm. Streptavidin biosensors (Forte Bio catalog: 18-5019 lot: 1405301) were equilibrated with Kinetic buffer for 10 min and then loaded with 50 nm of biotinylated cynomolgus properdin. In the association phase, selected anti-properdin antibodies or kinetic buffer blank 10 μg / mL were added to biosensors preloaded with biotinylated human properdin, respectively. These results show weak binding of AB005, AB006, AB007 and AB008 to cynomolgus properdin.
[0174] Example 3 Alternative Pathway Hemolysis Assay Figure 4 shows an alternative pathway-mediated hemolysis assay based on the formation of terminal complement complexes on the surface of rabbit red blood cells (rRBCs). The formation of these complexes results in the lysis of rRBCs. Agents that inhibit the formation of complement complexes are expected to inhibit cell lysis. Various anti-properdin antigen-binding fragments were tested to assess their effect on cell lysis mediated by alternative complement activation. An "assay plate" was prepared by diluting 40% normal human serum in gelatin veronal buffer (GVB) supplemented with 10 mM EGTA and 10 mM MgCl2 (e.g., 1600 μL of normal human serum into 2400 μL of GVB supplemented with 10 mM EGTA and 10 mM MgCl2). 50 μL of this solution was dispensed into each well of an assay plate (polystyrene). Dilution plates (polypropylene) were then prepared by adding 50 μL / well of 2x mAbs (e.g., anti-properdin Fab) in GVB supplemented with 10 mM EGTA and 10 mM MgCl2 at concentrations ranging from 0 to 100 nM to the appropriate wells. As a positive control, rabbit red blood cells were incubated in distilled water (100% cell lysis), and as a negative control, red blood cells were incubated in GVB containing 10 mM EDTA and 10 mM MgCl2, respectively (0% cell lysis).
[0175] 50 μL / well was transferred from the dilution plate to the assay plate. The assay plate was left at room temperature for the next step. 400 μL of rRBCs were washed 4 times with 1 mL of GVB supplemented with 10 mM EGTA and 10 mM MgCl2. After each wash, the rRBCs were spun at 2600 rpm for 1 minute. After the final wash, the rRBCs were resuspended in 300 μL of GVB supplemented with 10 mM EGTA and 10 mM MgCl2 to a volume of 400 μL. 50 μL of washed rRBCs were resuspended to 1 mL in GVB supplemented with 10 mM EGTA and 10 mM MgCl2. 30 μL of this dilution was added to the 100 μL sample prepared in the assay plate, resulting in 1.5 × 10 per well. 6cells were obtained. The plates were incubated at 37°C for 30 min. The plates were then centrifuged at 1000×g for 5 min and 85 μL of the supernatant was transferred to a 96-well flat-bottom plate. Hemolysis was determined by measuring the OD at 415 nm. At 415 nm, the stepwise decrease in light scattering (due to lysis of intact cells) was measured as a function of concentration. For calculations, anti-properdin V was used. HH Total inhibition was calculated at each concentration and the results expressed as a percentage of the unlisted control.
[0176] Example 4 Monovalent Anti-Properdin V to Properdin HH Antibody binding kinetics In FIG. 6, anti-properdin V HH Antibodies AB007 and AB008 were each flowed over the immobilized sensor surface at known concentrations, and the response level (RU) was plotted versus time in the sensorgram.
[0177] Anti-properdin V HH The binding affinities of the antibodies were determined and the results are summarized in Table 3 below.
[0178] [Table 3] Example 5 Binding kinetics of bispecific anti-properdin antibodies to properdin and complement secondary hemolysis assay A bispecific construct was made based on the above anti-properdin construct linked with a linker to an anti-albumin construct. Binding to properdin and complement secondary hemolysis was measured in the same assay as above. The sequence of the construct is shown in Table 4 below.
[0179] [Table 4] JPEG2024116321000005.jpg178170JPEG2024116321000006.jpg178170JPEG2024116321000007.jpg215170JPEG2024116321000008.jpg177170Figure 7 shows kinetic binding measurements performed on an Octet instrument (ForteBio Inc.). All washing, dilution and measurements were performed in Kinetic buffer (ForteBio catalog 185032) with plates shaking at 1000 rpm. Streptavidin biosensors (Forte Bio catalog 18-5019 lot 1405301) were equilibrated with Kinetic buffer for 10 min and then loaded with 50 nM biotinylated human properdin. In the association phase, selected anti-properdin antibodies or kinetic buffer blank at 10 μg / mL were added to the biosensors preloaded with biotinylated human properdin, respectively. These results show the binding of TPP-2225, TPP-2591, TPP-3071, TPP-3072 and TPP-3261 to human properdin. These results show strong binding to human properdin by all constructs.
[0180] Figures 8A-8B show the results of an alternative pathway-mediated hemolysis assay based on the formation of terminal complement complexes on the surface of rabbit red blood cells (rRBCs). The formation of these complexes results in the lysis of rRBCs. Agents that inhibit the formation of complement complexes are expected to inhibit cell lysis. Various bispecific anti-properdin antigen-binding constructs were tested to evaluate their effect on cell lysis mediated by alternative complement activation. An "assay plate" was prepared by diluting 40% normal human serum in gelatin veronal buffer (GVB) supplemented with 10 mM EGTA and 10 mM MgCl2 (e.g., 1600 μL of normal human serum into 2400 μL of GVB supplemented with 10 mM EGTA and 10 mM MgCl2). 50 μL of this solution was dispensed into each well of the assay plate (polystyrene). Dilution plates (polypropylene) were then prepared by adding 50 μL / well of 2x mAbs (e.g., anti-properdin Fab) to appropriate wells in GVB supplemented with 10 mM EGTA and 10 mM MgCl2 at concentrations ranging from 0 to 100 nM. As a positive control, rabbit red blood cells were incubated in distilled water (100% cell lysis), and as a negative control, red blood cells were incubated in GVB containing 10 mM EDTA and 10 mM MgCl2, respectively (0% cell lysis).
[0181] 50 μL / well was transferred from the dilution plate to the assay plate. The assay plate was left at room temperature for the next step. 400 μL of rRBCs were washed 4 times with 1 mL of GVB supplemented with 10 mM EGTA and 10 mM MgCl2. After each wash, the rRBCs were spun at 2600 rpm for 1 minute. After the final wash, the rRBCs were resuspended in 300 μL of GVB supplemented with 10 mM EGTA and 10 mM MgCl2 to a volume of 400 μL. 50 μL of washed rRBCs were resuspended to 1 mL in GVB supplemented with 10 mM EGTA and 10 mM MgCl2. 30 μL of this dilution was added to the 100 μL sample prepared in the assay plate, resulting in 1.5 × 10 per well. 6cells were obtained. The plates were incubated at 37°C for 30 min. The plates were then centrifuged at 1000×g for 5 min and 85 μL of the supernatant was transferred to a 96-well flat-bottom plate. Hemolysis was determined by measuring the OD at 415 nm. At 415 nm, the stepwise decrease in light scattering (due to lysis of intact cells) was measured as a function of concentration. For calculations, the total inhibition was calculated at each concentration of anti-properdin antibody construct and the results were expressed as a percentage of the unlisted control.
[0182] Figures 8A to 8B show hemolysis mediated by TPP-2221, TP-2222, TP-2223, TP-2224 and TP-2225 in human (Figure 8A) and cynomolgus (Figure 8B) serum. The control antibody is an anti-properdin antibody. Figures 9A to 9B show hemolysis mediated by TPP-2225, TPP-2951, TPP-3261, TPP-3071 and TPP-3072 in human (Figure 9A) and cynomolgus (Figure 9B) serum.
[0183] 10A-B, 11A-B, and 12A-B show the binding kinetics of TPP-3261, TPP-2951, and TPP-2225 to human and cynomolgus properdin.
[0184] Tables 5 to 9 below show the binding affinity and IC50 values of each construct.
[0185] [Table 5]
[0186] [Table 6]
[0187] [Table 7]
[0188] [Table 8]
[0189] [Table 9]
[0190] Other embodiments All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0191] It will be understood that the compositions and methods described herein are capable of further modification, and that this description is intended to cover any variation, use, or adaptation in accordance with the principles broadly disclosed herein, including such departures from the present disclosure as are applicable to the essential features described above and within the scope of known or customary in the art in accordance with the claims.
Claims
1. A fusion protein comprising a first monovalent antibody or antigen-binding fragment thereof and a second monovalent antibody or antigen-binding fragment thereof, A fusion protein, wherein the first monovalent antibody or antigen-binding fragment thereof comprises a VHH domain that specifically binds to human properdin.
2. The fusion protein of claim 1 , wherein the second monovalent antibody or antigen-binding fragment thereof is humanized.
3. The fusion protein of claim 1 , wherein the first monovalent antibody or antigen-binding fragment thereof is linked to the second monovalent antibody or antigen-binding fragment thereof by a linker.
4. The fusion protein of claim 3 , wherein the linker is a polyglycine linker.
5. The fusion protein of claim 4, wherein the polyglycine linker comprises the sequence GGGGD (SEQ ID NO: 63), GGGGS (SEQ ID NO: 1), GGGGA (SEQ ID NO: 100) or GGGGE (SEQ ID NO: 64).
6. The fusion protein of claim 5 , wherein the polyglycine linker comprises the sequence GGGGE (SEQ ID NO: 64).
7. The fusion protein of claim 1 , wherein the second monovalent antibody or antigen-binding fragment thereof specifically binds to albumin.
8. The fusion protein of claim 1 , wherein the second monovalent antibody or antigen-binding fragment thereof is linked to the N-terminus of the first monovalent antibody or antigen-binding fragment thereof that binds to human properdin.
9. The fusion protein of claim 1 , wherein the fusion protein inhibits the activity of human properdin.
10. A pharmaceutical for treating a disease mediated by abnormal regulation of the alternative complement pathway, comprising the fusion protein according to claim 1 as an active ingredient.
11. The pharmaceutical composition according to claim 10, wherein the disease is autoimmune thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS) or paroxysmal nocturnal hemoglobinuria (PNH).
12. The pharmaceutical composition of claim 11 , wherein the fusion protein inhibits alternative pathway membrane attack complex assembly.
13. The pharmaceutical composition according to claim 12, which inhibits alternative complement pathway-dependent hemolysis.
14. A pharmaceutical composition comprising the fusion protein of claim 1 as an active ingredient.
